Browse News
Filter News
Found 318 articles
-
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025
12/5/2023
Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it has strengthened its commercial organization with the promotion of Glenn E. Pauly to Chief Commercial Officer and the appointments of Dina Lynch to Vice President of Market Access, and Nate Greene to Vice President of Brand Marketing.
-
Spiral Therapeutics Welcomes New Investment, Cementing Its Leadership in Neurotology
8/30/2023
Spiral Therapeutics, Inc., a clinical-stage company focused on delivering therapies for inner ear disorders, announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.
-
Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors
5/31/2023
Ashvattha Therapeutics today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics President and CEO, Mahesh Karande to the Board of Directors.
-
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
3/29/2023
Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.
-
COEUS Holdings Names Dean Hakanson, MD Chief Medical Officer
1/11/2023
COEUS Holdings and its subsidiaries today announced it has appointed Dean Hakanson, MD, to the role of Chief Medical Officer.
-
Otonomy Announces Change in Stock Exchange Listing
12/22/2022
Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at the open of business on December 23, 2022.
-
Otonomy Provides Corporate Update - December 19, 2022
12/19/2022
Otonomy, Inc. announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including the proceeds from the sale of any pipeline assets.
-
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation
12/1/2022
Applied Genetic Technologies Corporation, announced the successful completion of the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited .
-
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation
11/29/2022
Applied Genetic Technologies Corporation, announced that a portfolio company of Syncona Limited has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.
-
*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*
11/22/2022
Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders:
-
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022
11/14/2022
Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, sent the following letter to stockholders.
-
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/10/2022
Otonomy, Inc. reported financial results for the quarter ended September 30, 2022 and provided an update on its product pipeline and corporate activities.
-
Hearing Loss Disease Treatment Market Size, Share, Growth, Trends | Report 2022-2030
11/10/2022
Hearing loss has a serious impact on an individual’s growth and development. According to WHO, globally 430 million people or approximately 5% of the world’s population require attention and action for their hearing disability.
-
Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022
11/3/2022
Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, sent the following letter to shareholders:
-
Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation
10/26/2022
Applied Genetic Technologies Corporation and a newly established portfolio company of Syncona Limited, announced the commencement of the previously announced tender offer for all of the issued and outstanding shares of common stock of AGTC at a price of $0.34 per share in cash, at the closing of the transaction, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.
-
Syncona to Acquire Applied Genetic Technologies Corporation
10/24/2022
AGTC announced that it has entered into a definitive agreement pursuant to which a newly established portfolio company of Syncona Limited, will acquire AGTC, through a tender offer, for approximately $23.5 million in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50.0 million pursuant to contingent value rights.
-
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
10/13/2022
Otonomy, Inc. today announced that the clinical evaluation of higher doses for OTO-413 (0.75 mg and 1.50 mg) in patients with hearing loss demonstrated no clinically meaningful improvement for patients from baseline across multiple speech-in-noise (SIN) hearing tests.
-
AGTC to Participate in Upcoming September 2022 Investor Conferences
9/1/2022
Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.
-
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
8/1/2022
Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all timepoints.
-
AGTC to Participate in Upcoming Investor Conferences - Aug 01, 2022
8/1/2022
Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.